Incyte Corporation v. Sun Pharmaceutical Industries, Ltd., decided May 7, 2025

This appeal concerns a preliminary injunction previously granted by the United States District Court for the District of New Jersey, which prevented Sun Pharmaceutical from launching its drug Leqselvi. The core of the dispute involves Incyte's claim of patent infringement related to its patent on deuterated ruxolitinib, a drug used to treat autoimmune disorders, and Sun Pharmaceutical's launch of a similar product for alopecia areata. The appellate court focuses on whether the district court correctly found irreparable harm to Incyte, ultimately reversing the preliminary injunction based on a finding that Incyte would not be the first to market regardless of Sun Pharmaceutical's actions due to Incyte's product development timeline. Full case summary here: https://www.cafcnewsbriefs.com/post/incyte-corporation-v-sun-pharmaceutical-industries-ltd-decided-may-7-2025-precedential